New Metal-Based Drugs for Cancer Treatment: Single Molecules, Nanomaterials, and Beyond

Topic Information

Dear Colleagues,

The search for new therapeutic alternatives to combat cancer has found in the transition elements a very abundant source of compounds and nanostructures with different geometric arrangements and reactivity that provide unique opportunities to interact with varying sites of recognition and exert mechanisms of action other than those drugs that are currently used to kill tumor cells. These features not only provide new tools independently but also could provide advantages enhancing concomitantly or sequentially the effect of known antineoplastic agents. In this Topic, the most recent findings regarding preclinical studies of metallodrugs, including but not limited to synthesis, characterization, simulation, computational modeling, and theoretical approach to new antiproliferative and antitumor agents, qualitative/quantitative structure-activity studies, bio-speciation/bioaccumulation, interaction with specific enzymes and nucleic acids, cytotoxicity, genotoxicity, teratogenicity, and general toxicity will be outlined. Submissions of original papers and focused reviews are welcome.

Dr. Juan Carlos García-Ramos
Dr. Yanis Toledano-Magaña
Dr. Gener José Avilés Rodríguez
Dr. Rodrigo Galindo-Murillo
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	3.9	5.2	2013	14.6 Days	CHF 2600
Cancers cancers	4.5	8.0	2009	17.4 Days	CHF 2900
Future Pharmacology futurepharmacol	-	-	2021	19.2 Days	CHF 1000
Journal of Clinical Medicine jcm	3.0	5.7	2012	16 Days	CHF 2600
Pharmaceutics pharmaceutics	4.9	7.9	2009	15.5 Days	CHF 2900

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomedicines Cancers Future Pharmacology JCM Pharmaceutics

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 2066 KiB)

21 pages, 4839 KiB  

Open AccessArticle

Heteroleptic Copper(II) Complexes Containing 2′-Hydroxy-4-(Dimethylamino)Chalcone Show Strong Antiproliferative Activity

by Zdeněk Trávníček, Tomáš Malina, Ján Vančo, Marek Šebela and Zdeněk Dvořák

Pharmaceutics 2023, 15(2), 307; https://doi.org/10.3390/pharmaceutics15020307 - 17 Jan 2023

Cited by 3 | Viewed by 2424

Abstract

A series of six heteroleptic copper(II) complexes with 2′-hydroxy-4-(dimethylamino)chalcone (HL) with the composition [Cu(N-N)(L)]NO₃ (1–6), where N-N stands for dmbpy = 5,5′-dimethyl-2,2′-bipyridine (1), bphen = 4,7-diphenyl-1,10-phenanthroline (2), dbbpy = 4,4′-di-tert-butyl-2,2′-bipyridine (3 [...] Read more.

A series of six heteroleptic copper(II) complexes with 2′-hydroxy-4-(dimethylamino)chalcone (HL) with the composition [Cu(N-N)(L)]NO₃ (1–6), where N-N stands for dmbpy = 5,5′-dimethyl-2,2′-bipyridine (1), bphen = 4,7-diphenyl-1,10-phenanthroline (2), dbbpy = 4,4′-di-tert-butyl-2,2′-bipyridine (3), nphen = 5-nitro-1,10-phenanthroline (4), bpy = 2,2′-bipyridine, (5), and dpa = 2,2′-dipyridylamine (6), was prepared and thoroughly characterized. The in vitro cytotoxicity screening on eight human cancer cell lines identified complex 2, containing the bulkiest N-donor ligands (bphen) as highly cytotoxic against cancer cells, with IC₅₀ values ranking from 1.0 to 2.3 μM, with good selectivity and low toxicity against healthy human fetal lung fibroblasts MRC-5. The cell-based assays, involving the most effective complex 2 in A2780 cancer cells, revealed its strong pro-apoptotic effects based on the effective activation of caspases 3/7, ROS overproduction, and autophagy in the A2780 cells while not impeding the cell cycle and mitochondrial membrane functions. The cellular uptake studies in A2780 and 22Rv1 cells uncovered no intracellular transport of the cationic complex 2, supporting the hypothesis that the in vitro anticancer effects of complex 2 are based on the combined extrinsic activation of apoptosis and autophagy induction. Full article

(This article belongs to the Topic New Metal-Based Drugs for Cancer Treatment: Single Molecules, Nanomaterials, and Beyond)

►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1